CreativeOne Wealth LLC Purchases 6,417 Shares of Johnson & Johnson $JNJ

CreativeOne Wealth LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 22.7% in the first quarter, Holdings Channel.com reports. The firm owned 34,658 shares of the company’s stock after acquiring an additional 6,417 shares during the period. CreativeOne Wealth LLC’s holdings in Johnson & Johnson were worth $5,748,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Lantz Financial LLC increased its holdings in Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after purchasing an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $453,000. Apexium Financial LP grew its holdings in shares of Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after acquiring an additional 2,310 shares in the last quarter. Joel Isaacson & Co. LLC grew its holdings in shares of Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after acquiring an additional 2,526 shares in the last quarter. Finally, State of Wyoming grew its holdings in shares of Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after acquiring an additional 10,279 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on JNJ shares. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Bank of America raised their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Trading Down 1.0%

Shares of JNJ stock opened at $176.63 on Wednesday. The firm has a 50 day moving average price of $164.44 and a two-hundred day moving average price of $159.60. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $425.39 billion, a PE ratio of 18.89, a price-to-earnings-growth ratio of 2.27 and a beta of 0.41. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the business posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.